LOS ANGELES, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP reminds investors of the upcoming November 18, 2025 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Jasper Therapeutics, Inc. (“Jasper” or the “Company”) (NASDAQ: JSPR) securities between November 30, 2023 and July 3, 2025, inclusive (the “Class Period”).

NEWTOWN, Pa. , Nov. 10, 2025 /PRNewswire/ -- Edelson Lechtzin LLP is investigating potential violations of the federal securities laws involving Soleno Therapeutics, Inc. ("Soleno" or "the Company") (NASDAQ: SLNO), resulting from allegations of providing potentially misleading business information to the investing public.

LOS ANGELES, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP reminds investors of the upcoming November 20, 2025 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired RCI Hospitality Holdings, Inc. (“RCI” or the “Company”) (NASDAQ: RICK) securities between December 15, 2021 and September 16, 2025, inclusive (the “Class Period”).

LOS ANGELES, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP reminds investors of the upcoming November 18, 2025 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired KBR, Inc. (“KBR” or the “Company”) (NYSE: KBR) securities between May 6, 2025 and June 19, 2025, inclusive (the “Class Period”).

Gilead Sciences, Inc. ( GILD ) UBS Global Healthcare Conference 2025 November 10, 2025 11:00 AM EST Company Participants Andrew Dickinson - Chief Financial Officer Presentation Unknown Analyst Good morning, everyone. My name is [ Dina Elmonshed.

InflaRx N.V. ( IFRX ) Discusses Topline Phase 2a Data in Chronic Spontaneous Urticaria and Hidradenitis Suppurativa November 10, 2025 8:00 AM EST Company Participants Jan Medina - Head of Investor Relations & VP Niels Riedemann - Co-Founder, CEO & Executive Director Camilla Chong - Chief Medical Officer Conference Call Participants Steven Seedhouse - Cantor Fitzgerald & Co., Research Division Ryan Deschner - Raymond James & Associates, Inc., Research Division Andreas Argyrides - Oppenheimer & Co. Inc., Research Division Will Soghikian - Leerink Partners LLC, Research Division Dev Prasad - Lucid Capital Markets, LLC, Research Division Presentation Jan Medina Head …

NEW YORK, Nov. 10, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of MoonLake Immunotherapeutics (NASDAQ: MLTX) between March 10, 2024 and September 29, 2025, both dates inclusive (the “Class Period”), of the important December 15, 2025 lead plaintiff deadline.

NEWTOWN, Pa. , Nov. 10, 2025 /PRNewswire/ -- Edelson Lechtzin LLP is investigating potential violations of the federal securities laws involving Arcturus Therapeutics Holdings Inc. ("Arcturus") (NASDAQ: ARCT), resulting from allegations of providing potentially misleading business information to the investing public.

LOS ANGELES, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP reminds investors of the upcoming December 8, 2025 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired aTyr Pharma Inc. (“aTyr” or the “Company”) (NASDAQ: ATYR) common stock between November 7, 2024 and September 12, 2025, inclusive (the “Class Period”).

LOS ANGELES, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP reminds investors of the upcoming December 15, 2025 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Baxter International, Inc. (“Baxter” or the “Company”) (NYSE: BAX) common stock between February 23, 2022 and July 30, 2025, inclusive (the “Class Period”).

WLFC's Q3 earnings fall slightly due to higher taxes and expenses, but reported a 25% revenue surge. Management raises its quarterly dividend on strong leasing demand.

Although the revenue and EPS for Organon (OGN) give a sense of how its business performed in the quarter ended September 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

TaskUs posts solid Q3 results with earnings and revenues surpassing estimates, driven by strong AI Services and Trust & Safety growth.

PHILADELPHIA , Nov. 10, 2025 /PRNewswire/ -- National plaintiffs' law firm Berger Montague PC announces a class action lawsuit against Fluor Corporation (NYSE: FLR) ("FLR" or the "Company") on behalf of investors who purchased or acquired shares during the period from February 18, 2025 through July 31, 2025 (the "Class Period"). Investor Deadline: Investors who purchased or acquired FLR securities during the Class Period may, no later than November 14, 2025 , seek to be appointed as a lead plaintiff representative of the class.

Maplebear (CART), better known as Instacart, posted better-than-expected results as shoppers placed more orders and spent more money on them.

LOS ANGELES, Nov. 10, 2025 (GLOBE NEWSWIRE) -- So Cal Gyms, LLC, a Planet Fitness Franchisee, has opened its newest location in Los Angeles in the Hyde Park neighborhood at 3230 W. Slauson Ave.

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz reminds investors of the upcoming November 12, 2025 deadline to participate as a lead plaintiff in the securities fraud class action lawsuit filed on behalf of investors who acquired V.F. Corporation (“VFC” or the “Company”) (NYSE: VFC) securities between October 27, 2022 and May 20, 2025, inclusive (the “Class Period”). IF YOU ARE AN INVESTOR WHO LOST MONEY ON V.F. CORPORATION (VFC), CLICK HERE TO PARTICIPATE IN THE SECURITIES FRAU.

Regeneron Pharmaceuticals, Inc. ( REGN ) Discusses Factor XI Development Program and Clinical Data in Hematology Pipeline November 10, 2025 8:30 AM EST Company Participants Ryan Crowe - Senior Vice President of Investor Relations & Strategic Analysis George Yancopoulos - Co-Founder, President, Chief Scientific Officer & Co-Chairman L. Sirulnik - Senior Vice President of Clinical Development Unit Head & Hematology David Gutstein Conference Call Participants Brian Abrahams - RBC Capital Markets, Research Division Tyler Van Buren - TD Cowen, Research Division David Risinger - Leerink Partners LLC, Research Division Simon Baker - Rothschild & Co Redburn, Research Division Malcolm Hoffman …

LOS ANGELES, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP reminds investors of the upcoming December 23, 2025 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired James Hardie Industries plc (“James Hardie” or the “Company”) (NYSE: JHX) common stock (previously American Depositary Shares until the Company's conversion to common stock on July 1, 2025) between May 20, 2025 and August 18, 2025, inclusive (the “Class Period”). IF YOU SUFFERED A LOSS ON YOUR JAMES HARDIE INVESTMENTS, CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING CLAIMS …

Cogent Biosciences, Inc. earns a Strong Buy rating due to positive phase 3 PEAK results for bezuclastinib + Sunitinib in 2nd-line GIST. Company's combination therapy showed a significant mPFS improvement (16.5 vs. 9.2 months) and higher ORR (46% vs. 26%) over Sunitinib monotherapy in 2nd-line GIST patients. Upcoming catalysts include NDA filings for GIST in 1H 2026 and NonAdvSM by end of 2025, plus phase 2 APEX results for AdvSM in December 2025.